Asia
The medical regulator’s green light is a milestone in the global fight against specific types of late-stage blood cancer, as CAR T-cell therapy has been found to be effective against them.
Founded in 2014, Insilico focuses on using artificial intelligence for drug discovery and development.
Yao has more than 15 years of experience in the cell and gene therapy fields. He also established and directed the Cell Therapy R&D business unit, with a focus on CAR-T development.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
The research collaboration will see the development of bispecific antibodies and CAR-T cell products.
A busy week for clinical trial news as the ASCO meeting wrapped up and the European Hematology Association 2021 Virtual Congress began. Read on for more.
Beigene presented results from three pivotal trials at the 26th EHA2021 Virtual Congress for the effectiveness of their checkpoint inhibitor tislelizumab in relapsed or refractory lymphoma.
According to the CDC, the Delta variant now accounts for more than 6% of infections in the U.S. and may be responsible for 18% of cases in some Western states.
The Pennsylvania-based eye disease company had to change its application from an Emergency Use Authorization to a full BLA approval.
This week, multiple companies have partnered in attempts to bring forth new therapies. BioSpace takes a look at some of these announcements.
PRESS RELEASES